MedTrace Logo

Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19

NCT04724720 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2022-04-12

No results posted yet for this study

Summary

The overall objective of this study is to evaluate the clinical efficacy of oral famotidine in symptomatic non-hospitalized patients with confirmed COVID-19. This study is expected to enroll up to 84 patients with mild to moderate symptoms divided into each of the two study arms. Clinical outcomes of the two treatment arms will be compared. This study will be conducted virtually/remotely.

Conditions

Interventions

DRUG

Famotidine

Standard or care treatment plus prescribed famotidine

DRUG

Placebo

Standard of care treatment plus placebo

Sponsors & Collaborators

Principal Investigators

  • Tobias Janowitz, MD, PhD · Cold Spring Harbor Laboratory

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-19
Primary Completion
2021-05-03
Completion
2022-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04724720 on ClinicalTrials.gov